Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanogen Extends Celera License Agreement for Additional IVD Products

Abstract:
Nanogen, Inc. (Nasdaq:NGEN), developer of molecular-biology and rapid diagnostic products, announced today that Celera Corporation has extended its license agreement of Nanogen's patent portfolio in molecular biology to develop additional diagnostic products.

Nanogen Extends Celera License Agreement for Additional IVD Products

San Diego, CA | Posted on October 23rd, 2008

Celera Corporation will use Nanogen's Minor Groove Binder (MGB) technology to develop in vitro diagnostic products for cardiovascular and oncological applications. This is an expansion of the original license agreement, signed in 2004, in which Celera licensed the technology for development of a hepatitis C genotyping products for individual patient management, monitoring and treatment. Under the Agreement, Celera Corporation will pay Nanogen an upfront license fee, milestone and anniversary fees throughout development, and a royalty on sales of the diagnostic products.

"The Celera license expands our current license into new and exciting molecular diagnostic applications," said Howard Birnsdorf, Nanogen CEO. "Our MGB technology has been licensed to a number of companies and the expanded field for Celera strongly supports the value of our technology in real-time PCR."

Nanogen's MGB technology is licensed broadly in various fields and is now an integral component in thousands of PCR probe products. Nanogen has more than 35 reagent and kit products that are sold for clinical diagnostic use under the MGB Alert® and Q-PCR Alert™ brands.

####

About Nanogen, Inc.
Nanogen provides innovative, high-quality diagnostic products to clinicians, physicians and researchers worldwide, making it easier to predict, diagnose and, ultimately, help treat disease in a timely fashion. The company's products include molecular diagnostic kits and reagents and kits for rapid, point-of-care diagnostic tests. Nanogen has pioneered research in areas involving nanotechnology, biomarkers, and molecular biology to bring better results to diagnostics and healthcare.

About Celera

Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at www.celera.com.

For more information, please click here

Contacts:
Nanogen, Inc.
Nicholas Venuto
Chief Financial Officer
858-410-4600
Kelly Gann
Marketing Communications
858-410-4667

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

'Exotic' material is like a switch when super thin April 18th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

Nanomedicine

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

High-temperature plasmonics eyed for solar, computer innovation April 17th, 2014

Announcements

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

'Exotic' material is like a switch when super thin April 18th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

Patents/IP/Tech Transfer/Licensing

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Nanoparticles cause cancer cells to self-destruct April 3rd, 2014

A*STAR's Simtech collaboration agreements to accelerate the growth and development of the microfluidics industry April 1st, 2014

Dolomite releases novel droplet-on-demand sequencing and droplet generation microfluidic system April 1st, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE